Creating incentives for genomic research to improve targeting of therapies

Nature Medicine

Volumn 10, Issue 12, 2004, Pages 1289-1291

  Evans, Barbara J ^a,b   Flockhart, David A ^a,c   Meslin, Eric M ^a,c,d  

^a Indiana University   (United States)

^b Law Firm of Baker and Daniels ^*  (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB; TRASTUZUMAB;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; ECONOMIC ASPECT; ETHICS; FINANCIAL MANAGEMENT; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; GOVERNMENT; HEALTH CARE; HEALTH CARE COST; HEALTH PROMOTION; HUMAN; INVESTMENT; LAW; NOTE; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; MOTIVATION; PHARMACOGENETICS; PUBLIC POLICY; TREATMENT FAILURE;

EID: 11144286046     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1204-1289     Document Type: Note

References (26)

1. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Report No. EMEA/CMP/3070/01. Position paper on terminology in pharmacogenetics. (European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, London, 2002).
2. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues (Nuffield Council on Bioethics, London, 2003).
3. Lesko, L.J. et al. J. Clin. Pharmacol. 43, 342-358 (2003).
4. Lynch, T.J. et al. N. Engl. J. Med. 350, 2129-2139 (2004).
5. Paez, J.G. et al. Science 304, 1497-1500 (2004).
6. Peakman, T. & Arlington, S. Drug Discovery World 2, 35-40 (2001).
7. Rägo, L. WHO Drug Information 17, 84-91 (2003).
8. Dickson, M., Hurst, J. & Jacobzone, S. Survey of pharmacoeconomic assessment activity in eleven countries. (Organization for Economic Cooperation and Development, Paris, 2003).
9. Lesko, L.J. & Woodcock, J. Nat. Rev. Drug Discov. 3, 763-769 (2004).
10. US Department of Health and Human Services. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products (Food and Drug Administration, Washington, DC, 2004).
11. US Department of Health and Human Services. Center for Medicare & Medicaid Services. National Health Expenditures Tables. Table 3: National health expenditures by source of funds and type of expenditure: selected calendar years 1997-2002 (US Department of Health and Human Services, CMS, Washington, DC, 2004).
12. Lazarou, J., Pomeranz, B.H. & Corey, P.N. J. Am. Med. Assoc. 279, 1200-1205 (1998).
13. Agrawal, M. & Emanuel, E.J. J. Am. Med. Assoc. 290, 1075-1082 (2003).
14. Jess, M. Natural Gas Monthly DOE/EIA-1030(97/05), vii-xxi (1997).
15. World Health Organization. The world health report 2003. Annex Table 5: Selected national health account indicators: measured levels of expenditure on health, 1997-2001 (World Health Organization, Geneva, 2004).
16. Guttmacher, A.E. & Collins, F.S. N. Engl. J. Med. 349, 996-998 (2003).
17. Hensley, S. Wall Street Journal. B:1 (Eastern ed., April 27, 2004).
18. Epstein, A.M., Lee, T.H. & Hamel, M.B. N. Engl. J. Med. 350, 406-410 (2004).
19. Dodds-Smith, I. & Bagley, G. in Global Counsel Life Sciences Handbook 2004/05. p 77-85 (Practical Law Company, London, 2004).
20. Rawlins, M.D. N. Engl. J. Med. 351, 1383-1385 (2004).
21. Institute of Medicine. Care without coverage: too little, too late (National Academies Press, Washington, DC, 2002).
22. US Department of Health and Human Services. Center for Medicare & Medicaid Services. Transcript No. CAG-00157N (2/12/2003): Medicare Coverage Advisory Committee meetings for implantable cardioverter defibrillators (ICDs) (US Department of Health and Human Services, Center for Medicare & Medicaid Services, Washington, DC, 2003).
23. US Department of Energy, Energy Information Administration. Report No. DOE/EIA-0602(5) Energy policy act transportation study: interim report on natural gas flows and rates (EPACT) Ch. 2, p. 9 (US Department of Energy, Energy Information Administration, Washington, DC, 1995).
24. US Congressional Budget Office, Electric utilities: deregulation and stranded costs (US Congressional Budget Office, Washington, DC, 1998).
25. US Department of Energy, Energy Information Administration. Electricity reform abroad and U.S. investment. Ch. 2 (U.S. Department of Energy, Energy Information Administration, Office of Energy Markets and End Use, Washington, DC, 1997).
26. Michaels, R.J. Regulation 16, 20-31 (1993).